Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children’s Oncology Group

Gillani R, Shulman DS, DelRocco NJ, Klega K, Han R, Krailo MD, Slack JC, Tanhaemami M, Ward A, Bainer V, Ricker C, Sparks J, Bailey KM, Reed DR, DuBois SG, Leavey P, Mascarenhas L, Grohar PJ, Church AJ, Crompton BD, Janeway KA. Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2025 Nov 3:JCO2500157. doi: 10.1200/JCO-25-00157. Epub ahead of print. PMID: 41183255; PMCID: PMC12614438.

Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children’s Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials.